Area percent raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-11-22 and is reviewed periodically as new material appears.
Orthogonal methods reduce the chance that a single technique misses an impurity. Capillary electrophoresis separates by charge-to-size ratio and can resolve variants that co-elute under one set of HPLC conditions. Amino acid analysis reports composition after hydrolysis and confirms the presence of expected residues. Karl Fischer titration measures water content, while ion chromatography can quantify counterions. No single number captures all aspects of sample quality, so reports often combine several measurements.
Peptide purity testing uses separation methods to estimate the proportion of a sample that corresponds to the target sequence. Reverse-phase high-performance liquid chromatography is the most common technique, separating peptides by hydrophobicity on a nonpolar column. Ultraviolet detection at 214 nm records peptide bonds and aromatic residues. The resulting chromatogram is reported as area percent, which reflects relative absorbance rather than absolute mass. This distinction matters because water, counterions, and residual solvents do not appear in the peptide peak.
Mass spectrometry provides an identity check that complements chromatographic purity. Electrospray ionization or matrix-assisted laser desorption/ionization measures the mass-to-charge ratio of intact peptides. A match to the expected molecular mass supports correct sequence length and terminal groups. Mass accuracy alone does not prove that every peak in a liquid chromatogram is the target peptide. It also does not directly quantify how much water or counterion remains in a lyophilized powder.
Reported purity values can differ between laboratories even for the same sample. Variations arise from column chemistry, mobile-phase composition, gradient slope, detection wavelength, injection load, and integration rules. Area percent also assumes that all species have similar response factors, which is not always true. Method validation examines specificity, linearity, accuracy, precision, limit of detection, and limit of quantitation. When comparing certificates, the method description and representative chromatogram are as important as the headline percentage.
Purity and potency are related but distinct concepts in peptide testing. Purity describes the proportion of the main peptide relative to other detected substances, while potency refers to the biological or functional activity of a defined amount. A highly pure peptide can still have low potency if it is misfolded, aggregated, or chemically modified at a critical residue. Conversely, a less pure preparation may retain high activity if the impurities are inactive. Clear reporting separates these attributes and states the assay used for each.
Peptide purity specifications describe which tests define an acceptable lot and how results are reported. A certificate of analysis commonly lists a reverse-phase HPLC purity value, a mass spectrometry identity result, water content, counterion content, and residual solvent data. The specification may set a minimum area percent, such as 95% or 98%, depending on the intended use and grade. No universal threshold applies to all peptides, because sequence length, hydrophobicity, and manufacturing route influence achievable purity.
| Property | Value | Notes |
|---|---|---|
| Primary purity method | Reverse-phase HPLC | Separates peptides by hydrophobicity; reports area percent. |
| Identity confirmation | Mass spectrometry | Electrospray or MALDI; matches observed mass to expected sequence. |
| Orthogonal separation | Capillary electrophoresis | Separates by charge-to-size ratio; complements HPLC. |
| Water content | Karl Fischer titration | Water dilutes peptide mass and affects concentration calculations. |
| Counterion | Trifluoroacetate or acetate | Common counterions alter net peptide content in lyophilized powder. |
Regulatory and accreditation expectations depend on the peptide's intended use. Research reagents may be tested with in-house methods, while pharmaceutical development follows validated procedures and pharmacopeial chapters where applicable. Method validation commonly examines accuracy, precision, specificity, linearity, range, and limits of detection and quantitation. Laboratories accredited to ISO/IEC 17025 must document competence, equipment calibration, and uncertainty. Comparing purity results across laboratories remains difficult because different columns, gradients, detection wavelengths, and integration rules can change reported values; open questions include how best to standardize impurity identification and reporting for diverse peptide products.
Quality control for peptides places purity testing within a documented system that includes specifications, test methods, and acceptance criteria. A certificate of analysis typically reports appearance, chromatographic purity, mass confirmation, and storage conditions. System suitability checks, blank injections, and reference standards help ensure that an analytical run is valid. Traceability requires records of sample preparation, instrument settings, and data processing. No single purity threshold applies to all peptides or uses, so specifications are set according to the intended application and risk assessment.
Independent verification is used when a supplier result needs confirmation or when a material supports regulated work. A second laboratory can repeat reverse-phase HPLC and mass spectrometry on the same sample. Discrepancies may arise from different columns, gradients, detection wavelengths, or sample preparation. Moisture uptake and counterion content can lower net peptide mass without changing area percent. Documentation of methods and raw data helps distinguish analytical variation from a true quality difference.
Quality control for peptides begins with a documented specification that states the required purity, identity, and appearance. Suppliers often release research-grade material at 95% or greater by HPLC area, but this threshold is not universal. A certificate of analysis typically records the lot number, sequence, test methods, and measured values. The document allows a user to compare batches and to trace deviations. Specifications should match the intended use rather than a generic label.
Handling and storage influence measured purity, and peptides can oxidize, deamidate, aggregate, or adsorb to surfaces over time. Lyophilized powders stored at -20 °C or lower are generally more stable than solutions, though some sequences require different conditions. Repeated freeze-thaw cycles can promote aggregation and loss, so testing after storage checks whether purity has changed. Stability-indicating methods compare stressed and unstressed samples to detect degradation pathways. Light exposure and pH can also accelerate modification.
Solid-phase peptide synthesis can produce truncated sequences when coupling reactions fail. Deletion peptides lack one or more internal residues, while truncation peptides end prematurely. Side reactions include aspartimide formation, oxidation of methionine, and aggregation during chain assembly. Crude synthetic peptides therefore contain target peptide plus related impurities, counterions, residual solvents, and water. Purification by preparative chromatography reduces these impurities but does not remove every closely related species, including some that differ by a single amino acid.
Quality control specifications for peptides typically include appearance, identity, purity by RP-HPLC, water content, counterion content, and residual trifluoroacetic acid. Karl Fischer titration measures water, while ion chromatography or elemental analysis can quantify counterions. Purity specifications may be set at 95% or 98% area percent, but the appropriate threshold depends on the application. For research reagents, a lower purity may be acceptable if identity is confirmed. For assays sensitive to impurities, higher purity and orthogonal testing are often required.
Quality control includes system suitability, blank injections, and reference standards. System suitability checks column performance and retention time reproducibility, while blank runs detect carryover or mobile-phase contaminants. Reference standards help calibrate retention time and detector response. Without these controls, a purity value is difficult to compare across laboratories or over time. Documentation of instrument settings and integration parameters is also part of quality control, and acceptance criteria should be set before samples are analyzed.
Impurity profiles can include deletion peptides, oxidized forms, truncated sequences, and residual solvents. Some impurities arise during synthesis, cleavage, or purification, while others form during storage. Purity testing often focuses on peptide-related impurities, whereas residual solvents and counterions require separate assays. The significance of a given impurity depends on its amount and properties, which may not be established for a research peptide. Reporting an impurity profile is more informative than reporting a single purity number.
Peptide purity specifications describe the minimum acceptable result from a defined test. A certificate of analysis may list HPLC purity, mass spectrometry identity, appearance, and counterion content. Specifications are method-dependent, so a value obtained with one gradient or wavelength may differ from another. For research use, common thresholds include 95% and 98% by RP-HPLC, but the appropriate limit depends on the application. The specification should always name the analytical method and acceptance criterion.
== First recorded observation == In his 14 June 1680 letter to the Royal Society, Antonie van Leeuwenhoek described an experiment he carried out by filling two identical glass tubes about halfway with crushed pepper powder, to which some clean rain water was added. Van Leeuwenhoek sealed one of the glass tubes with a flame and left the other open. Several days later, he discovered in the open glass tube 'a great many very little animalcules, of divers sort having its own particular motion.' Not expecting to see any life in the sealed glass tube, Van Leeuwenhoek saw to his surprise 'a kind of living animalcules that were round and bigger than the biggest sort that I have said were in the other water.' The conditions in the sealed tube had become quite anaerobic due to the consumption of oxygen by aerobic microorganisms. In 1913, Martinus Beijerinck repeated Van Leeuwenhoek's experiment and identified Clostridium butyricum as a prominent anaerobic bacterium in the sealed pepper infusion tube liquid. Beijerinck commented:
The army throughout the spring of 1943 was significantly reinforced and grew to a strength of 1,100 tanks and 250,000 men by July 1943. It was to form the southern spearhead in the Battle of Kursk. The army tried but failed to break through the Soviet defences around Kursk. It then fought a series of defensive battles throughout the remainder of 1943 to hold back the Red Army's Lower Dnieper Strategic Offensive Operation. By November 1943, the Soviets had reached Kiev and the 4th Panzer Army was tasked to defend the city. The Soviet aim was to take the city and break the rail link with Army Group Center or envelop Army Group South. But even though the Soviets had liberated Kiev, broken the Dnieper line, and inflicted massive casualties, the 4th Panzer Army held on and the Soviets failed to break the rail link.
=== Europe === A marketing authorisation application for 68Ga-PSMA-11 (INN Gallium (68Ga) gozetotide), under the brand name Illucix, was made to the Danish Medicines Agency, on behalf of several EU countries and the UK. Approval is expected in 2022. In 2022 a marketing authorisation application was made by the manufacturer of 18F-DCFPyL (branded Pylclari) to the European Medicines Agency. Polish manufacturer and distributor of radiopharmaceutical procuts, Polatom, has been granted a US patent for a 99mTc-PSMA-T4 kit. In the UK, Tc-99m labelled PSMA has product authorisation but lacks funding.
Having let slip one chance after another of reaching an accommodation with more moderate black leaders, Rhodesia's whites seem to have made the tragic choice of facing black nationalism over the barrel of a gun rather than the conference table. The downhill road toward a race war in Rhodesia is becoming increasingly slippery with blood. At this point, ZANU's alliance with FRELIMO and the porous border between Mozambique and eastern Rhodesia enabled large-scale training and infiltration of ZANU/ZANLA fighters. The governments of Zambia and Botswana were also emboldened sufficiently to allow resistance movement bases to be set up in their territories. Guerrillas began to launch operations deep inside Rhodesia, attacking roads, railways, economic targets and isolated security force positions, in 1976.
Sources: en.wikipedia.org
=== Menu === The menu, which features hot specialty subs, salads, and other seasonal items, takes inspiration from the firehouse with names like Hook & Ladder, Engineer, and Firehouse Hero. The subs are prepared with meats and cheeses, on toasted sub rolls, and served "Fully Involved" with vegetables and condiments. Chris and Robin remain in charge of the menu, and work alongside their director of product development Jay Miller, who joined the company in 2017.
Pro-opiomelanocortin (POMC) is a precursor polypeptide with 241 amino acid residues. POMC is synthesized in corticotrophs of the anterior pituitary from the 267-amino-acid-long polypeptide precursor pre-pro-opiomelanocortin (pre-POMC), by the removal of a 26-amino-acid-long signal peptide sequence during translation. POMC is part of the central melanocortin system.
==== New drug smuggling conviction and deportation to Belgium ==== On the evening of 19 July 2008, Olofsson and three other people were arrested next to Apelviken's campsite in Varberg. The police had him under surveillance for eight months and he was suspected of being the head in a large drug operation. At the same time, the police cracked down on a drug transport at Årsta partihallar in Stockholm. A total of six people were arrested in Stockholm and Varberg on suspicion of serious drug offenses. Olofsson was charged at the end of 2008 for trying to smuggle in 100 kilos of amphetamine and 76 kilos of cannabis from the Netherlands. The police of Östergötland had tracked down the drug smugglers through reconnaissance films and wiretapping since 2007. The trial began on 2 June 2009 and he was sentenced on 31 July 2009 to 14 years in prison, followed by life-time deportation, by the Linköping District Court for an aggravated drug offense and attempted aggravated drug offense. He was sentenced to nine years in prison for his drug dealing and was forced to serve another five years for continuing his crime following a previous conviction. When he returned to crime after his release in 2005, the district court had confiscated five years of his conditional release of seven years and thus Olofsson's sentence was in practice 14 years. On 7 December 2009, the prison sentence was upheld by Göta Court of Appeal. Until the autumn of 2012, Olofsson was incarcerated at Saltvik Prison in Härnösand before he was moved to Kumla Prison.
Ammonium acetate, also known as spirit of Mindererus in aqueous solution, is a chemical compound with the formula NH4CH3CO2. It is a white, hygroscopic solid and can be derived from the reaction of ammonia and acetic acid. It is available commercially.
Phenazopyridine produces a vivid color change in urine, typically to a dark orange to reddish color. This effect is common and harmless and indeed a key indicator of the presence of the medication in the body. Users of phenazopyridine are warned not to wear contact lenses, as phenazopyridine has been known to permanently discolor them. Furthermore, it tends to leave an orange-yellow stain on surfaces (including fabrics) it comes in contact with. These color changes can be concerning for patients, who may mistake them for the presence of blood in the urine. Phenazopyridine can cause headaches, upset stomach (especially when not taken with food), or dizziness. Less frequently it can cause a noticeable yellowish pigment change in the skin or eyes. This is due to a depressed excretion via the kidneys causing a buildup of the medication in the skin, and normally indicates a need to discontinue usage. Other such side effects include fever, confusion, shortness of breath, skin rash, and swelling of the face, fingers, feet, or legs. Long-term use may cause yellowing of nails. Phenazopyridine should be avoided by people with glucose-6-phosphate dehydrogenase deficiency, because it can cause hemolysis (destruction of red blood cells) due to oxidative stress. It has been reported to cause methemoglobinemia after overdose and even normal doses. In at least one case, the patient had pre-existing low levels of methemoglobin reductase, which likely predisposed her to the condition. It has also been reported to cause sulfhemoglobinemia. Phenazopyridine is an azo dye.
Sources: en.wikipedia.org
It measures the relative ultraviolet absorbance area of peptide peaks, usually at 214 nm. It does not directly measure mass, water, counterions, or co-eluting species.
HPLC and mass spectrometry answer different questions: HPLC estimates separation purity, while mass spectrometry confirms molecular mass. Orthogonal methods reduce the risk that one technique misses an impurity.
Yes. Area percent excludes water, counterions, residual solvents, and any species that co-elute with the target peak. Net peptide content can therefore be lower than the reported HPLC purity.
Purity percentages vary because each laboratory uses its own column, mobile phase, gradient, detection wavelength, and integration settings. A 95% value from one method may not equal 95% from another method. Comparative assessment requires the same validated procedure or an orthogonal cross-check.